One of the most important knowledge gaps in HIV/SIV vaccine research relates to the biological properties of viruses that are responsible for mucosal transmission. Within this HIVRAD consortium, this project will address this priority area by taking advantage of our laboratory's recent discovery of a novel strategy for identifying mucosally transmitted HIV-1 and SIV viral genomes (Salazar et al., J Virol, 2008; Keele, PNAS, 2008;Salazar, J Exp Med, 2009;Keele, J Exp Med, 2009). This strategy, which is based on single genome amplification, sequencing and analysis of plasma viral RNA within the context of a model of random virus evolution, identifies those viruses that are actually responsible for transmission and productive infection. This innovation, in turn, makes possible for the first time the molecular cloning and biological characterization of such transmitted/founder virus genomes. In this project, we propose to extend this enabling technology to the SIV-macaque infection model to test the following hypothesis: Molecular clones of transmitted/founder SIVs will reveal the particular properties of cell tropism, receptor and co-receptor usage, and neutralization phenotype that are necessary and sufficient for successful transmission via intrarectal, intravaginal and intravenous infection routes.
Specific aims i nclude: 1. To identify and enumerate transmitted/founder viruses in Indian rhesus macaques following intrarectal, intravaginal and intravenous infection with new genetically diverse SIVsmm strains. To moleculariy clone full-length genomes of transmitted/founder viruses responsible for productive infection by intrarectal, intravaginal and intravenous routes. To determine the in vitro biological properties of molecular clone-derived transmitted/founder viruses. To prepare stocks of transmitted/founder viruses for in vivo testing in Indian rhesus macaques. Results from these studies will shed new light on the molecular mechanisms underiying mucosal HIV/SIV transmission, identify new targets for vaccine-elicited immune responses, and generate a much needed set of new genetically-diverse SIV challenge strains for transmission, pathogenesis and vaccine research.
Using the transmitted/founder virus clones generated in this project we will, for the first time, be able to address whether viruses that are transmitted across mucosal surfaces are phenotypically different from viruses that are transmitted intravenously. This information will eliminate a major roadblock to our understanding ofthe eariiest HIV-1 infection events and is thus critically important for vaccine development.
|Smedley, Jeremy; Turkbey, Baris; Bernardo, Marcelino L et al. (2014) Tracking the luminal exposure and lymphatic drainage pathways of intravaginal and intrarectal inocula used in nonhuman primate models of HIV transmission. PLoS One 9:e92830|
|Ma, Dongzhu; Jasinska, Anna J; Feyertag, Felix et al. (2014) Factors associated with siman immunodeficiency virus transmission in a natural African nonhuman primate host in the wild. J Virol 88:5687-705|
|Roederer, Mario; Keele, Brandon F; Schmidt, Stephen D et al. (2014) Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-8|
|Ma, Dongzhu; Jasinska, Anna; Kristoff, Jan et al. (2013) SIVagm infection in wild African green monkeys from South Africa: epidemiology, natural history, and evolutionary considerations. PLoS Pathog 9:e1003011|
|Lopker, Michael; Easlick, Juliet; Sterrett, Sarah et al. (2013) Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87:5477-92|
|Parrish, Nicholas F; Gao, Feng; Li, Hui et al. (2013) Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 110:6626-33|
|Liao, Hua-Xin; Lynch, Rebecca; Zhou, Tongqing et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496:469-76|
|Liao, Hua-Xin; Tsao, Chun-Yen; Alam, S Munir et al. (2013) Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87:4185-201|
|Vaccari, Monica; Keele, Brandon F; Bosinger, Steven E et al. (2013) Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 87:3538-48|
|Kong, Rui; Li, Hui; Bibollet-Ruche, Frederic et al. (2012) Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 86:947-60|
Showing the most recent 10 out of 11 publications